sitagliptin / metformin hydrochloride mylan
mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. triple kombinasjon terapi) som et tillegg til diett og trening hos pasienter ikke kontrollert på deres maksimal tolerert dose av metformin og en sulphonylurea. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
sitagliptin / metformin hydrochloride accord
accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, type 2 - legemidler som brukes i diabetes - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. triple kombinasjon terapi) som et tillegg til diett og trening hos pasienter ikke kontrollert på deres maksimal tolerert dose av metformin og en sulphonylurea. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.
natriumhydrogenkarbonat braun 500 mmol/ l
b. braun melsungen ag - natriumhydrogenkarbonat - infusjonsvæske, oppløsning - 500 mmol/ l
natriumhydrogenkarbonat braun 167 mmol/ l
b. braun melsungen ag - natriumhydrogenkarbonat - infusjonsvæske, oppløsning - 167 mmol/ l
natriumhydrogenkarbonat braun 0.5 mmol/ ml
b. braun melsungen ag - natriumhydrogenkarbonat - konsentrat til infusjonsvæske, oppløsning - 0.5 mmol/ ml
natriumklorid abcur 500 mg
abcur ab - natriumklorid - tablett, filmdrasjert - 500 mg
natriumklorid b. braun 9 mg/ ml
b. braun melsungen ag - natriumklorid - oppløsningsvæske til parenteral bruk - 9 mg/ ml
natriumklorid b. braun 9 mg/ ml
b. braun melsungen ag - natriumklorid - infusjonsvæske, oppløsning - 9 mg/ ml
natriumklorid baxter 9 mg/ ml
baxter medical ab - natriumklorid - infusjonsvæske, oppløsning - 9 mg/ ml
natriumklorid baxter 9 mg/ ml
baxter medical ab - natriumklorid - infusjonsvæske, oppløsning - 9 mg/ ml